Guidelines for noninvasive tests for evaluation of Clostridioides difficile severity and prognosis were published in September 2021 by the Infectious Diseases Society of America and Society for Healthcare Epidemiology of America in Clinical Infectious Diseases.
These are some of the highlights of the guidelines without analysis or commentary. For more information, go directly to the guidelines by clicking the link in the reference.
Updated guidelines on the management of Clostridioides difficile infection in adults were published in September 2021 by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA) in Clinical Infectious Diseases.
In patients with a first Clostridioides difficile infection (CDI) episode, fidaxomicin is recommended instead of a standard course of vancomycin.
In those with recurrent CDI episodes, fidaxomicin (standard or extended-pulsed regimen), rather than a standard course of vancomycin, is recommended.
In patients who experience a recurrent CDI episode within the last 6 months, use bezlotoxumab as a co-intervention in combination with standard-of-care (SOC) antibiotics rather than SOC antibiotics only.
Medscape © 2021 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Clostridioides difficile Clinical Practice Guidelines (IDSA/SHEA, 2021) - Medscape - Nov 03, 2021.